Micrus Corporation announced today the appointment of John Kilcoyne as President and Chief Executive Officer. In addition to serving as President and CEO, Mr. Kilcoyne has become a member of Micrus' Board of Directors.
Mr. Kilcoyne brings 21 years of operating experience to Micrus. Prior to joining Micrus, Mr. Kilcoyne served as the Chief Executive Officer of Solace Therapeutics, a privately held medical device company. From November 1997 to January 2001 Mr. Kilcoyne held the role of President and CEO of Endonetics. During his time at Endonetics, the company conceived, developed and commercialized two devices that allowed Mr. Kilcoyne to successfully negotiate the acquisition of Endonetics by Medtronic. In addition Mr. Kilcoyne's experience includes senior management positions at Guidant/ACS and Boston Scientific. Mr. Kilcoyne received his B.S. from Cornell University.
Michael R. Henson, Chairman of Micrus commented, "John is a seasoned executive with extensive experience in bringing breakthrough technologies to market in both private and public company settings. John will continue to develop our corporate infrastructure and product pipeline to meet the rapidly increasing worldwide demand for innovative products to treat neurovascular diseases."
"I am extremely excited about the future at Micrus. I believe the recent release of our Cerecyte(TM) bioactive coils, combined with our product development pipeline, positions us well for significant revenue growth and market share gains," stated Mr. Kilcoyne.
About Micrus Corporation (www.micruscorp.com)
Micrus Corporation, with offices in Sunnyvale, CA and Yverdon, Switzerland, is a privately held medical device company which develops, manufactures and markets highly differentiated, proprietary devices and delivery systems for neuro-endovascular applications. Micrus' advanced technology, including the Micrus MicroCoil System for the treatment of cerebral aneurysms, is registered and distributed in the United States and Europe, as well as a number of other countries. Micrus is proud to have expanded its MicroCoil line in 2004 to include Cerecyte(TM), a new polymer-loaded, bioactive MicroCoil, and the Concourse 14 microcatheter, featuring excellent trackability and tip-shape retention. Micrus is also developing CereStent(TM), a line of innovative intracranial stents.
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including general market conditions, developments affecting Micrus sales momentum, public funding, operations, and other risks detailed from time to time by Micrus Corporation. Micrus disclaims any intent or obligation to update these forward-looking statements.